Jobs / Canada / Astrazeneca Pharmaceuticals Lp
Director of PET Manufacturing
Astrazeneca Pharmaceuticals Lp · 🇨🇦 Canada – Hamilton – Longwood Road South
Sponsorship verdict
No sponsorship evidence yet
No government record and no wording either way. Not a refusal — ask the recruiter.
- No government sponsor record hereNo government sponsor record covers this employer in this country.
- The posting doesn’t mention sponsorshipSilence isn’t a refusal — ask the recruiter before investing much time.
- No salary bar for this routeCanada has no single salary bar: the employer usually needs a positive LMIA. Pay at or above the provincial median wage + 20% (e.g. C$36.92/h in Ontario) puts it in the high-wage stream. Source: https://www.canada.ca/en/employment-social-development/services/foreign-workers/median-wage.html, rules effective 2026-07-17.
- Confirmed live todayWhen a source last listed this job as open.
Canada: Express Entry no longer awards ranking points for job offers (since 25 Mar 2025); a job offer still counts toward Federal Skilled Worker eligibility.
A verdict summarises public evidence; it is not legal advice and never a guarantee — the employer and the immigration authority decide. Sign in to factor in where you can already work.
Or apply yourself on the official page →
Why not apply?
No register record and no sponsorship wording in the posting. Worth asking the employer before investing significant time.
SponsorApply flags time-wasters so your applications go where they can land. These come from the posting's own wording — read the original listing to confirm. See better-fit alternatives →
Sponsor Radar — Astrazeneca Pharmaceuticals Lp
No government sponsor record covers this employer in this country.
Past sponsorship or register membership never guarantees sponsorship for this vacancy or for you. Full Sponsor Radar for Astrazeneca Pharmaceuticals Lp →
About the role
Fusion Pharmaceuticals, part of the AstraZeneca Group, is redefining precision oncology with next‑generation radioconjugates that deliver powerful alpha‑emitting payloads directly to tumors. Our pipeline spans multiple first‑in‑class programs—backed by a GMP‑compliant, state‑of‑the‑art radiopharmaceutical facility in Hamilton, we’re turning cutting‑edge science into real‑world impact for patients. Join us at the forefront of radiopharma innovation and be part of turning breakthrough science into meaningful outcomes for patients—come build what’s next with us! Note: This role is 5 days per week onsite. Role Summary The Director of PET Manufacturing, External Network is responsible for developing and leading a robust external manufacturing network for positron emission tomography (PET) radiopharmaceuticals. The role focuses on building strategic partnerships with contract manufacturing organizations, hospital-based radiopharmacies, academic production sites, and commercial PET manufacturing providers to ensure reliable, compliant, and scalable supply. This leader will define and execute the external manufacturing strategy, oversee network performance, and work cross-functionally to support clinical and commercial objectives across the PET portfolio. The position requires deep expertise in PET radiopharmaceutical manufacturing , external supply models, GMP , quality oversight, technology transfer, and distribution constraints associated with short half-life isotopes. The individual will operate at the interface of technical operations, quality, regulatory, supply chain, and business development to establish a high-performing external network capable of meeting evolving pipeline and market needs. This role reports into the Head of Radioconjugate Manufacture and Development. Key Responsibilities • External network strategy : Define and implement the strategy for building an external PET manufacturing network across target geographies, aligned to portfolio demand, development milestones, and commercialization plans. • Partner identification and selection : Identify, assess, and prioritize potential external PET manufacturing partners, including CDMOs, nuclear pharmacies, academic centers, and regional radiopharmaceutical producers. • Due diligence and capability assessment : Lead technical, operational, quality, and business due diligence for prospective partners, evaluating cyclotron access, synthesis capability, aseptic processing, QC release, qualified personnel, capacity, distribution reach, and compliance maturity. • Network design : Develop the footprint model for external PET production, taking into account isotope half-life, patient scheduling, dose delivery windows, geographic coverage, redundancy needs, and business continuity requirements. • Contracting support : Partner with procurement, legal, finance, and business development teams to support commercial negotiations, quality agreements, supply agreements, statements of work, and performance frameworks. • Technology transfer and launch readiness : Oversee transfer of manufacturing processes, analytical methods, batch documentation, and operational practices into external sites, ensuring readiness for clinical supply and commercial launch. • Operational oversight : Establish governance and performance management processes for external manufacturing partners, including capacity planning, production reliability, right-first-time performance, deviation trends, change control, and on-time dose delivery. • Supply continuity and risk management : Build contingency plans and network resilience strategies to address cyclotron downtime, raw material shortages, site outages, transportation disruptions, and other risks inherent to PET manufacturing and distribution. • Cro